
SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...

Gleamer raises €27m in Series B funding round
Gleamer SAS’ financing round was led by Supernova Invest, co-led by Heal Capital and backed by Gleamer’s long-term partners XAnge, Elaia, Bpifrance...

Resistance blocker of immune checkpoint inhibitors gets patented
DT-9081, Domain Therapeutics’ selective EP4 receptor antagonist, preclinically synergised with PD1-checkpoint blockers and shrinked tumours by...

Smarter, faster, cheaper: Veeva shows how
Achieving the highest possible speed in innovation to meet patients’ unmet needs. That was the palpable goal all the pharmaceutical and life sciences...

French Carthera closes €37.5m Series B financing round
A prominent (undisclosed) investor led the round alongside the European Innovation Council Fund (EICF) and existing investors including Panakès...

Aboleris Pharma bags €27.3m in Series A Financing
AbolerIS Pharma SA’s financing was led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with...

Bacterial-fungal consortium denitrifies wastewater by 100%
Researchers from China and Germany have developed a new biotechnological approach to clean up waste water from anorganic nitrite and nitrate more...